FDA Panel Splits on Sanofi’s Diabetes NDA

Drug Industry Daily
A A
An FDA advisory committee deadlocked Thursday on the safety profile for Sanofi’s NDA for type 1 diabetes drug sotagliflozin.

To View This Article:

Login

Subscribe To Drug Industry Daily